Does Mounjaro Help with PCOS? What We Know Right Now

Step 1, Understanding what PCOS does to your metabolism

Polycystic ovary syndrome affects roughly one in ten women of reproductive age in the UK, and its metabolic impact is often underestimated. Most women with PCOS have some degree of insulin resistance, the body produces insulin normally but cells respond poorly to it. The pancreas compensates by releasing more, and that excess insulin stimulates the ovaries to produce androgens (male hormones) at higher-than-normal levels. Those androgens disrupt ovulation, drive irregular periods and contribute to symptoms like acne and unwanted hair growth.

Weight gain makes this cycle harder to break. Extra body fat, particularly around the abdomen, amplifies insulin resistance further. That is why weight management sits at the centre of most PCOS treatment plans, not as a cosmetic goal, but as a way of correcting a hormonal imbalance. The NHS's guidance on obesity treatment recognises this, noting that even a 5% reduction in body weight can meaningfully improve hormone levels and menstrual regularity in women affected by the condition.

This is where the question of whether Mounjaro helps with PCOS becomes genuinely interesting. Tirzepatide targets two gut-hormone receptors (GLP-1 and GIP) both of which play a role in how the body handles blood sugar and responds to insulin, and if you are wondering whether taking Mounjaro can cause diabetes rather than simply treating its risk factors, that question is worth exploring separately. It is the only dual-agonist of its kind licensed in the UK.

Step 2, What the evidence shows for tirzepatide and PCOS

No large randomised controlled trial has yet tested tirzepatide specifically in a PCOS population, so there is no licence claim for that indication and there should be no overstating of what is proven. That said, the biological logic is strong, and early clinical data are encouraging.

In the SURMOUNT-1 trial, published in the New England Journal of Medicine, tirzepatide produced an average body-weight reduction of around 20–21% at the 15mg dose over 72 weeks in adults with obesity and no diabetes. That degree of weight loss, if replicated in women with PCOS, would be expected to reduce circulating androgens significantly and improve ovulatory function, effects that studies of other weight-loss interventions have demonstrated repeatedly. Tirzepatide also independently improves insulin sensitivity beyond what weight loss alone explains, which matters specifically in PCOS.

Some smaller studies and clinical case series have reported improvements in menstrual regularity, androgen markers and quality of life in women with PCOS using GLP-1 class medicines. The evidence base is growing but is not yet definitive. For more on how the mechanism applies to PCOS specifically, the tirzepatide and PCOS overview covers this in more detail. Pending dedicated trials, prescribers assess PCOS on a case-by-case basis alongside its weight and metabolic profile.

Step 3, Eligibility: when Mounjaro can be prescribed if you have PCOS

Because Mounjaro is not licensed for PCOS itself, what matters clinically is whether you meet the weight-management licence criteria. That means a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition. PCOS with documented insulin resistance, pre-diabetes or hypertension would typically count as a qualifying condition at the lower threshold. Your NICE appraisal of tirzepatide (TA1026) sets out the NHS criteria, which are stricter; private prescribing follows the licensed SmPC thresholds instead.

A prescriber will want to understand your full picture: current medications (metformin is commonly used in PCOS and is generally compatible, but your prescriber will check), reproductive plans, and contraception. This is not box-ticking, it is where the clinical judgment happens. Eligibility also has an age dimension, and anyone asking whether teenagers can take Mounjaro will find that the answer involves specific clinical thresholds that differ from adult criteria. If you would like to explore how Mounjaro fits into a broader PCOS management plan, that page brings together the practical considerations.

One thing worth saying plainly: if you have spent years being told to simply lose weight without the hormonal context being taken seriously, this is a frustrating place to be. The research on tirzepatide does not dismiss that frustration, it addresses part of what makes weight management genuinely harder in PCOS than in the general population.

Step 4, Pregnancy, conception and what to do before you try

This is the section that carries the most weight. Mounjaro is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. Animal data raise concerns about foetal development at doses used in humans, and there are no adequate human studies. The MHRA's prescribing information is clear: effective contraception must be used during treatment.

For women with PCOS who hope that improved hormone balance might restore fertility, the timing question is real. If weight loss and improved insulin sensitivity lead to more regular ovulation, conception becomes more possible, sometimes sooner than expected. That is why contraception during treatment is not optional advice. If conception is your goal, the right conversation is with your prescriber and, ideally, your gynaecologist or fertility specialist before starting.

Our page on Mounjaro and fertility addresses this directly, including the wash-out guidance before trying to conceive. And if you are already prescribed Mounjaro and have questions about alcohol or other lifestyle factors, this page on drinking on Mounjaro covers the specifics. For a broader look at where Mounjaro sits among weight-management options, our treatment overview is a useful reference.

A GPhC-registered prescriber at nume (sorry, at nume's free consultation) reviews every case the same day. Your PCOS history, your medications and your goals all factor in before anything is prescribed.